Pharmaceuticals, Biotechnology and Life Sciences
Novartis has announced the launch of Novartis Access in Kenya, the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer.
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).
Quantum Pharma Plc has announced that it had signed an exclusive agreement with Futura Medical plc the healthcare company which is focused on advanced transdermal technology, to manufacture and make available MED2002, Futura’s novel treatment for erectile dysfunction, as an unlicensed medicine (special) in the UK (the “Agreement”).
Premaitha Health plc, developer of the IONA test, the first CE-marked non-invasive prenatal screening test (NIPT) has expanded its in-house NIPT screening service by opening a dedicated laboratory which triples clinical capacity in response to demand for the IONA test from clinicians.
Johnson & Johnson has had sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014.
Skipanon Brand Seafoods LLC of Warrenton, Oregon is voluntarily recalling ALL LOTS, ALL SIZES of ALL Skipanon brand seafoods canned products because it has the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illness or death. Consumers are warned not to use the product even if it does not look or smell spoiled.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health.
TF Supplements of Houston, TX, is voluntarily recalling RHINO 7 3000 capsules packaged in a bottle containing six capsules and Rhino 7 Platinum 3000 Capsules packaged in a single blister packs hang card count.
Eli Lilly and Company and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy.